Nurix Therapeutics (NRIX) EBITDA Margin (2019 - 2026)
Nurix Therapeutics' (NRIX) quarterly EBITDA Margin came in at 1041.73% in Q2 2026, down 93205.0% year-on-year from N/an in Q2 2025, and up 29.59% on a QoQ basis from 1479.45% in Q1 2026.
Nurix Therapeutics (NRIX) EBITDA Margin (2019 - 2026) Analysis & Trends
Nurix Therapeutics (NRIX) has 8 years of EBITDA Margin data on file, last reported at 1041.73% in Q2 2026.
- On a quarterly basis, EBITDA Margin fell 93205.0% year-over-year to 1041.73% in Q2 2026; TTM through May 2026 was 982.37%, a 72162.0% decrease from a year earlier, with the FY2025 full-year figure at 340.16%, up 5036.0% from the prior year.
- EBITDA Margin for Q2 2026 stood at 1041.73%, up from 1479.45% in the prior quarter.
- Over the last five years, EBITDA Margin for NRIX reached as high as 87.25% in Q2 2023 and fell as low as 1479.45% in Q1 2026.
- Historically, EBITDA Margin has averaged 515.13% across 5 years, with a median of 417.18% in 2022.
- Across the five-year window, EBITDA Margin surged 41877 bps in 2023 and slumped 113878 bps in 2026, its largest moves.
- Year by year, EBITDA Margin stood at 717.82% in 2022, then jumped by 58 bps to 299.06% in 2023, then plunged by 63 bps to 486.73% in 2024, then retreated by 26 bps to 612.03% in 2025, then slumped by 70 bps to 1041.73% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 1041.73% in Q2 2026, 1479.45% in Q1 2026, and 612.03% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Nurix Therapeutics | 2.64 Bn | 2.19 Bn | - | -1,041.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | -1,041.73% |
| Feb 28, 2026 | -1,479.45% |
| Nov 30, 2025 | -612.03% |
| Aug 31, 2025 | -1,157.65% |
| May 31, 2025 | -109.68% |
| Feb 28, 2025 | -340.67% |
| Nov 30, 2024 | -486.73% |
| Aug 31, 2024 | -433.83% |
| May 31, 2024 | -401.42% |
| Feb 29, 2024 | -272.65% |
| Nov 30, 2023 | -299.06% |
| Aug 31, 2023 | -216.67% |
| May 31, 2023 | -87.25% |
| Feb 28, 2023 | -338.60% |
| Nov 30, 2022 | -717.82% |
| Aug 31, 2022 | -432.93% |
| May 31, 2022 | -399.89% |
| Feb 28, 2022 | -444.28% |
| Nov 30, 2021 | -513.16% |
| Aug 31, 2021 | -282.84% |